Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)

NCT05456880 is registered in ClinicalTrials.gov with Beam Therapeutics Inc. as lead sponsor.

NCT NCT05456880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)
Lead sponsor
Beam Therapeutics Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 30, 2022
Completion date
February 29, 2028
Enrollment
15 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease